Biora Therapeutics Successfully Completes Restructuring Process

Core Viewpoint - Biora Therapeutics has successfully completed its court-supervised restructuring, emerging as a privately held company with a stronger balance sheet and new financing to support the development of its BioJet™ platform [1][2]. Group 1: Company Overview - Biora Therapeutics is a biotech company focused on developing the first swallowable autoinjector, aiming to revolutionize the delivery of biologic pharmaceuticals [3]. - The BioJet™ platform is designed to replace traditional injections with a needle-free, oral delivery method for macromolecules [3]. Group 2: Technology and Development - The BioJet technology autonomously delivers a variety of molecules, including proteins, peptides, and nucleic acids, with a capacity exceeding 300 microliters, allowing for doses greater than 50 milligrams [4]. - The company is positioned to accelerate the development of the BioJet platform, which can deliver industry-leading payloads in a commercially desirable format [2]. Group 3: Financial and Ownership Changes - Following the restructuring, ownership of Biora transitioned to certain lenders, including Davidson Kempner Capital Management LP, Context Capital Management LLC, and funds managed by Highbridge Capital Management LLC, with existing common shares being cancelled [2].